WuXi Biologics (Cayman) Inc
HKEX:2269
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.26
30.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
WuXi Biologics (Cayman) Inc
WuXi Biologics (Cayman) Inc
Net Issuance of Common Stock
WuXi Biologics (Cayman) Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Net Issuance of Common Stock
¥1.5B
|
CAGR 3-Years
-56%
|
CAGR 5-Years
214%
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genscript Biotech Corp
HKEX:1548
|
Net Issuance of Common Stock
$12.1m
|
CAGR 3-Years
-72%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Net Issuance of Common Stock
¥3.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
WuXi Biologics (Cayman) Inc
Glance View
WuXi Biologics (Cayman) Inc. emerged from the bustling arena of global pharmaceuticals as a beacon of innovation and flexibility in the biologics manufacturing space. Founded in 2010, this Chinese firm quickly established itself as a key player by offering a comprehensive suite of services that span the entire biologics development process. The company's strategy revolves around its "Follow-the-Molecule" business model, characterized by a symbiotic partnership with clients from the early stages of drug discovery through clinical development and all the way to commercial manufacturing. This approach ensures not only seamless integration across different development stages but also cultivates long-term relationships with clients, including startups and large pharmaceutical giants. Utilizing state-of-the-art technologies and an expansive network of manufacturing facilities around the globe, WuXi Biologics has positioned itself as an indispensable partner for firms looking to bring new biologics to market swiftly and efficiently. The revenue model of WuXi Biologics hinges on its ability to offer flexible, customer-centric solutions in a highly demanding industry. Unlike traditional pharmaceutical companies that solely profit from drug sales, WuXi Biologics earns money by leveraging its Contract Development and Manufacturing Organization (CDMO) platform to provide end-to-end services. This includes process development, clinical trials, regulatory submissions, and commercial production. The company capitalizes on strategic partnerships and its burgeoning pipeline of projects, earning fees at each stage of the drug development cycle. By ensuring proprietary access to its advanced technologies and broad capabilities, WuXi Biologics not only supports its clients' needs but also fortifies its revenue streams via milestone payments, service fees, and long-term manufacturing contracts. Such a business model not only diversifies its income but also mitigates risks associated with drug development uncertainty, allowing the company to thrive in the competitive global healthcare market.
See Also
What is WuXi Biologics (Cayman) Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
1.5B
CNY
Based on the financial report for Jun 30, 2024, WuXi Biologics (Cayman) Inc's Net Issuance of Common Stock amounts to 1.5B CNY.
What is WuXi Biologics (Cayman) Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
214%
The average annual Net Issuance of Common Stock growth rates for WuXi Biologics (Cayman) Inc have been -56% over the past three years , 214% over the past five years .
You don't have any saved screeners yet